Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Published Online
on April 4, 2002

Arteriosclerosis, Thrombosis, and Vascular Biology. 2002
Published online before print April 4, 2002, doi: 10.1161/01.ATV.0000017470.08363.AB
A more recent version of this article appeared on June 1, 2002
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
22/6/1018    most recent
01.ATV.0000017470.08363.ABv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Folsom, A. R.
Right arrow Articles by White, R. H.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Folsom, A. R.
Right arrow Articles by White, R. H.
Related Collections
Right arrow Energy metabolism
Right arrow Metabolism

Submitted on February 4, 2002
Accepted on March 25, 2002

Protein C, Antithrombin, and Venous Thromboembolism Incidence. A Prospective Population-Based Study

Aaron R. Folsom *; Nena Aleksic ; Lu Wang ; Mary Cushman ; Kenneth K. Wu ; and Richard H. White

From the Division of Epidemiology (A.R.F., L.W.), School of Public Health, University of Minnesota, Minneapolis; the Division of Hematology (N.A., K.K.W.), University of Texas Medical School, Houston; the Department of Medicine (M.C.), University of Vermont, Burlington; and the Division of General Medicine (R.H.W.), University of California-Davis, Sacramento.

* To whom correspondence should be addressed. E-mail: folsom{at}epi.umn.edu.

Abstract—Although deficiencies of protein C and antithrombin, 2 natural plasma anticoagulants, are known risk factors for venous thrombosis, population-based prospective incidence data on these associations are lacking. Venous thromboembolic events have been identified in adults in 2 longitudinal cohort studies, the Atherosclerosis Risk in Communities (ARIC) Study and the Cardiovascular Health Study (CHS). Incidence was examined in relation to prediagnostic plasma levels of protein C (ARIC Study only) and antithrombin. Over a mean of 8.1 years of follow-up, there were 130 incident venous thromboembolic events that were not due to cancer in the ARIC Study. The age-adjusted incidence was elevated 3.36-fold (95% CI 1.24 to 9.11) in the 1.1% of subjects with protein C values <2.0 mg/L compared with subjects with higher values. In contrast, in the ARIC Study and the CHS, there was no association between low plasma antithrombin and venous thromboembolism. In conclusion, in this population-based study, a low protein C, but not antithrombin, level has been determined to be associated with an increased incidence of venous thromboembolism. Attributable risk estimates suggest that low protein C levels account for {approx}2.5% of venous thromboembolic events in the ARIC population.


Key words: antithrombin • protein C • prospective study • venous thrombosis • pulmonary embolus